GPRC5A and in situ carcinoma: We found that the percentage of the Sca-1+Abcg1+subset within the in situ carcinoma tissue reached 2.5% (Fig. 6b), which was higher than the percentage observed in lung tissue samples from Gprc5a-deficient mice that had not yet developed tumors (Fig. 5c).